Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Burkhard Jaeger

Juergen Schroeder

Richard John Varsolona

Carl Alan Busacca

Svenja Renner

Markus Sauter

Georg Dziewas

Thomas Fachinger

Thilo Berkenbusch

Carsten Reichel

Cartsen Reichel

This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: 

Crystalline forms of a potent HCV inhibitor

The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups R, R, Rand Rhave the meanings given in the claims, as well as sulphonyl derivatives of formula and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.

Process for preparing aminocrotonylamino-substituted quinazoline derivatives

The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups R, R, Rand Rhave the meanings given in the claims, as well as sulphonyl derivatives of formula (XIII) and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases. 

The invention relates to a process for preparing optically active 5-hydroxy-3-ketoesters of formula A1 or A2, or one of the tautomers thereof,the use thereof for preparing optically active dihydropyrones of formula B, and the use of the dihydropyrones of formula B thus prepared as starting compounds for preparing pharmaceutically active compounds, particularly Tipranavir.

Process for preparing optically active dihydropyrones

The invention relates to a new process for preparing optically active dihydropyrones, new intermediate products which may be obtained by this synthesis, and their use as starting compounds in the preparation of pharmaceutically active compounds.

Growing community of inventors

Bingen, Germany

Burkhard Jaeger